Novo Nordisk’s weight loss drug semaglutide found to improve wellbeing
New results from a Phase IIIa study demonstrate benefits of drug for people with obesity ‘beyond weight loss’
Read More
Tag: semaglutide
Novo Nordisk plans study of oral semaglutide in obesity
Study will include approximately 1,000 people with obesity or overweight with comorbidities
Read More
FDA refuses Novo Nordisk’s once-weekly semaglutide
Company had been aiming for approval in type 2 diabetes
Read More
Lilly’s tirzepatide claims head-to-head trial win against injectable semaglutide
Tirzepatide demonstrated superior A1C and body weight reduction in type 2 diabetes
Read More
Novo Nordisk’s semaglutide cuts body weight in large-scale trial
Participants lost on average 14.9% of their baseline body weight
Read More
Novo Nordisk eyes EU approval for once-weekly semaglutide
Danish pharma is seeking approval for drug as a weight management therapy
Read More
Novo Nordisk’s AM833 shows early success in obesity trials
The firm is ‘encouraged’ by the performance of the drug, both as monotherapy and in combination with semaglutide
Read More
Oral semaglutide trumps Jardiance, Januvia, Victoza in type II diabetes
Type II diabetes costs the NHS £8.8 billion a year.
Read More
Recent Ozempic, Victoza data ‘promising’ for diabetic kidney disease
Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk talks exclusively to PharmaTimes.
Read More
Novo’s oral semaglutide bests MSD’s Januvia on HbA1c reduction
Novo Nordisk has presented data from a Phase IIIa study showing that an oral formulation of its GLP-1 analogue semaglutide was better at reducing blood sugar than MSD’s DPP-4 inhibitor Januvia in patients with type II diabetes.
Read More
Novo’s Ozempic beats Lilly’s Trulicity on weight loss
Novo Nordisk has announced new data showing that its once-weekly glucagon-like peptide 1 (GLP-1) receptor agonist Ozempic provided greater weight reductions than Eli Lilly’s rival drug Trulicity in adults with type II diabetes.
Read More
Novo’s oral semaglutide beats Lilly/Boehringer’s Jardiance
Novo Nordisk has announced headline data from the PIONEER 2 trial showing that oral semaglutide was better at improving HbA1c levels in patients with type II diabetes than Lilly’s and Boehringer Ingelheim’s Jardiance.
Read More
- US study reveals interferon combinations cause lupus symptoms and affect treatment
- NIHR and TJBCM announce new funding initiative for novel brain tumour research
- UKHSA and ICL confirm variant which plays key role in global surge of Strep A infections
- Study reveals heart failure device could monitor patients and prevent hospitalisation
- MIT’s new MRI brain light-detecting technique could support brain cell studies
